Lantheus stock is trading -26.99% below its average target price of $122.38 after dropping -3.4% during today's afternoon session. Analysts are giving the mid-cap Biotechnology company an average rating of buy and target prices ranging from $113.0 to $130.0 per share.
Lantheus has an average level of shares sold short, at 7.1% of its total share float. The stock's short ratio (also called days to cover) is 3.34. Since 2.81% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests.
Institutional investors own 101.3% of Lantheus's shares, which indicates they have a high level of confidence in the company.
Institutions Invested in Lantheus
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-03-31 | Blackrock Inc. | 11% | 7,807,737 | $697,660,365 |
| 2023-03-31 | Vanguard Group, Inc. (The) | 11% | 7,353,063 | $657,032,969 |
| 2023-03-31 | Alliancebernstein L.p. | 4% | 2,845,605 | $254,269,044 |
| 2023-03-31 | State Street Corporation | 3% | 2,324,952 | $207,746,093 |
| 2023-03-31 | Hood River Capital Management LLC | 2% | 1,633,626 | $145,972,656 |
| 2023-03-31 | Assenagon Asset Management S.A. | 2% | 1,454,887 | $130,001,432 |
| 2023-03-31 | Invesco Ltd. | 2% | 1,419,040 | $126,798,323 |
| 2023-03-31 | Dimensional Fund Advisors LP | 2% | 1,386,612 | $123,900,719 |
| 2023-03-31 | Geode Capital Management, LLC | 2% | 1,345,272 | $120,206,784 |
| 2023-03-31 | Price (T.Rowe) Associates Inc | 2% | 1,291,460 | $115,398,412 |
